Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Improving the Prognosis and Treatment of Osteoarthritis with Quantitative MRI

By BiotechDaily International staff writers
Posted on 20 May 2013
Print article
A new project’s goal is to assess multiple imaging and biochemical biomarkers to find more comprehensive ways to evaluate both the progression of the disease and the effectiveness of new treatments.

The Biomarkers Consortium (Bethesda, MD, USA; Mount Laurel, NJ, USA), a public-private partnership managed by the Foundation for the US National Institutes of Health (FNIH; Bethesda, MD, USA),reported that substantial progress is being made in the FNIH Osteoarthritis (OA) Biomarkers Project, which seeks to improve clinical outcomes for nearly 30 million people in the United States living with OA of the knee and for those at risk for developing the disease.

Preliminary findings from quantitative magnetic resonance imaging (qMRI) of femur, fibula, and patella periarticular bone area, three-dimensional (3D) bone shape and joint space width show significant differences between patients with progressive OA and nonprogressing control subjects at early study time points (baseline to 24 months) and are predictive of clinical OA progression in the knee over 48 months. This is the first report of changes of defined biomarkers of bone shape being predictive of OA progression and highlights their superior ability to measure early and subtle changes in OA progression compared to traditional radiographic measures. These findings were presented at the Osteoarthritis Research Society International (OARSI) World Congress, held in Philadelphia (PA, USA), April 2013.

The project, now into its second year, continues on an aggressive stride to investigate further quantitative and semiquantitative image evaluations of bone and cartilage changes in the knee joint by mid-2013. Furthermore, testing on 12 biochemical markers using serum and urine from the study cohort has begun to assess joint tissue metabolism. These biochemical markers can also provide a direct measure of drug effect and mechanism of action to help better refine customized treatments for OA.

The OA Biomarkers Project is being led by two scientists from OARSI, Dr. David Hunter at the University of Sydney and Dr. Virginia Byers Kraus at Duke University (Durham, NC, USA). The project is run under the direction of the Biomarkers Consortium, a public-private biomedical research partnership managed by the FNIH and combines expertise from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and pharmaceutical and biotech companies, academia, and disease-focused nonprofit organizations.

Related Links:
Biomarkers Consortium
Foundation for the US National Institutes of Health


Print article

Channels

Genomics/Proteomics

view channel
Image: Top: Overview of the structure of T-STAR STAR domain in complex with AUUAAA RNA. Bottom left: close up view of the specific recognition of the RNA. Bottom right: close up view of the KH dimerization interface (Photo courtesy of the University of Leicester).

Atomic Structures of Alternative Splicing Regulator Proteins May Lead to New Anticancer Drugs

A detailed structural analysis of two RNA-binding proteins that regulate alternate splicing of gene expression, which can lead to various types of cancer, is expected to aid in the development of drugs... Read more

Drug Discovery

view channel
Image: Naturally occurring clay from Kisameet Bay, Canada, exhibits potent antibacterial activity against multidrug-resistant pathogens (Photo courtesy of Kisameet Glacial Clay Inc.).

Antibiotic Resistant Bacteria Succumb to Treatment with Unique Natural Clay

A team of Canadian medical microbiologists has demonstrated the potential use of a unique type of natural clay for treating pathogenic bacteria that have become resistant to the commonly used antibiotics.... Read more

Business

view channel

Purchase Agreement to Boost Ebola Vaccine Development

A deal to help boost development of a vaccine to protect against Ebolavirus infection was finalized at the recent Davos Conference in Switzerland. Gavi (Geneva, Switzerland), the global alliance for vaccines and immunizations, announced that it would spend five million USD to purchase the Ebola vaccine under development... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.